Pegylated interferon alfa-2b monotherapy and pegylated interferon alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 8, 2007, Pages 3020-3022

  Kaymakoglu, Sabahattin ^a,i   Oguz, Dilek ^b   Gur, Gurden ^c   Gurel, Selim ^d   Tankurt, Ethem ^e   Ersöz, Galip ^f   Ozenirler, Seren ^g   Kalayci, Cem ^h   Poturoglu, Sule ^a   Cakaloglu, Yilmaz ^a   Okten, Atilla ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

^c BASKENT UNIVERSITY   (Turkey)

^d ULUDAG UNIVERSITY   (Turkey)

^e DOKUZ EYLUL UNIVERSITY   (Turkey)

^f EGE UNIVERSITY   (Turkey)

^g GAZI UNIVERSITY   (Turkey)

^h MARMARA UNIVERSITY   (Turkey)

ⁱ ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS E ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2B;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DEPRESSION; DIAGNOSTIC KIT; DRUG EFFICACY; FEMALE; FLU LIKE SYNDROME; HEPATITIS B; HUMAN; INJECTION SITE REACTION; LIVER BIOPSY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; THYROIDITIS; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2B; LAMIVUDINE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 34547634046     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00088-07     Document Type: Article

References (13)

1. Asselah, T., M. P. Ripault, C. Castelnau, N. Giuily, N. Boyer, and P. Marcellin. 2005. The current status of antiviral therapy of chronic hepatitis B. J. Clin. Virol. 34(Suppl. 1):S115-S124.
2. Buster, E. H., and H. L. Janssen. 2006. Antiviral treatment for chronic hepatitis B virus infection - immune modulation or viral suppression? Neth. J. Med. 64:175-185.
3. Chan, H. L. Y., N. W. Y. Leung, A. Y. Hui, V. W. Wong, C. T. Liew, A. M. Chim, F. K. Chan, L. C. Hung, Y. T. Lee, J. S. Tam, C. W. Lam, and J. J. Sung. 2005. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann. Intern. Med. 142:240-250.
4. Chin, R., and S. Locarnini. 2003. Treatment of chronic hepatitis B: current challenges and future directions. Rev. Med. Virol. 13:255-272.
5. Janssen, H. L., M. van Zonneveld, H. Senturk, S. Zeuzem, U. S. Akarca, Y. Cakaloglu, C. Simon, T. M. So, G. Gerken, R. A. de Man, H. G. Niesters, P. Zondervan, B. Hansen, S. W. Schalm, the HBV 99-01 Study Group, and the Rotterdam Foundation for Liver Research. 2005. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365:123-129.
6. Knodell, R. G., K. G. Ishak, W. C. Black, T. S. Chen, R. Craig, N. Kaplowitz, T. W. Kiernan, and J. Wollman. 1981. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431-435.
7. Lau, G. K., T. Piratvisuth, K. X. Luo, P. Marcellin, S. Thongsawat, G. Cooksley, E. Gane, M. W. Fried, W. C. Chow, S. W. Paik, W. Y. Chang, T. Berg, R. Flisiak, P. McCloud, N. Pluck, and the Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group. 2005. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 352:2682-2695.
8. Manns, M. P. 2002. Current state of interferon therapy in the treatment of chronic hepatitis B. Semin. Liver. Dis. 22(Suppl. 1):7-13.
9. Marcellin, P., G. K. Lau, F. Bonino, P. Farci, S. Hadziyannis, R. Jin, Z. M. Lu, T. Piratvisuth, G. Germanidis, C. Yurdaydin, M. Diago, S. Gurel, M. Y. Lai, P. Button, N. Pluck, and the Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. 2004. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 351:1206-1217.
10. Santantonio, T., G. A. Niro, E. Sinisi, G. Leandro, M. Insalata, A. Guastadisegni, D. Facciorusso, E. Gravinese, A. Andriulli, and G. Pastore. 2002. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. J. Hepatol. 36:799-804.
11. Tatulli, I., R. Francavilla, G. L. Rizzo, V. Vinciguerra, E. Ierardi, A. Amoruso, C. Panella, and A. Francavilla. 2001. Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B. J. Hepatol. 35:805-810.
12. Yurdaydin, C., H. Bozkaya, H. Cetinkaya, T. Sahin, D. Karaoguz, M. Toruner, O. Erkan, A. O. Heper, E. Erden, A. M. Bozdayi, and O. Uzunalimoglu. 2005. Lamivudine vs lamivudine and interferon combination treatment of HBeAg(-) chronic hepatitis B. J. Viral Hepat. 12:262-268.
13. Zarski, J. P., P. Marcellin, V. Leroy, C. Trepo, D. Samuel, N. Ganne-Carrie, K. Barange, V. Canva, M. Doffoel, P. Cales, and the Fédération nationale des Pôles de référence et des Réseaux Hépatites. 2006. Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases. J. Hepatol. 45:355-360.